1
|
An Up-to-Date Literature Review on Ventricular Assist Devices Experience in Pediatric Hearts. LIFE (BASEL, SWITZERLAND) 2022; 12:life12122001. [PMID: 36556366 PMCID: PMC9788166 DOI: 10.3390/life12122001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/31/2022] [Revised: 11/22/2022] [Accepted: 11/29/2022] [Indexed: 12/02/2022]
Abstract
Ventricular assist devices (VAD) have gained popularity in the pediatric population during recent years, as more and more children require a heart transplant due to improved palliation methods, allowing congenital heart defect patients and children with cardiomyopathies to live longer. Eventually, these children may require heart transplantation, and ventricular assist devices provide a bridge to transplantation in these cases. The FDA has so far approved two types of device: pulsatile and continuous flow (non-pulsatile), which can be axial and centrifugal. Potential eligible studies were searched in three databases: Medline, Embase, and ScienceDirect. Our endeavor retrieved 16 eligible studies focusing on five ventricular assist devices in children. We critically reviewed ventricular assist devices approved for pediatric use in terms of implant indication, main adverse effects, and outcomes. The main adverse effects associated with these devices have been noted to be thromboembolism, infection, bleeding, and hemolysis. However, utilizing left VAD early on, before end-organ dysfunction and deterioration of heart function, may give the patient enough time to recuperate before considering a more long-term solution for ventricular support.
Collapse
|
2
|
Butto A, Mao CY, Wright L, Wetzel M, Kelleman MS, Carboni MP, Dipchand AI, Knecht KR, Reinhardt Z, Sparks JD, Villa C, Mahle WT. Relationship of ventricular assist device support duration with pediatric heart transplant outcomes. J Heart Lung Transplant 2021; 41:61-69. [PMID: 34688547 DOI: 10.1016/j.healun.2021.09.011] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2020] [Revised: 09/21/2021] [Accepted: 09/22/2021] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND There is wide variability in the timing of heart transplant (HTx) after pediatric VAD implant. While some centers wait months before listing for HTx, others accept donor heart offers within days of VAD surgery. We sought to determine if HTx within 30 days versus ≥ 30 after VAD impacts post-HTx outcomes. METHODS Children on VAD pre-HTx were extracted from the Pediatric Heart Transplant Study database. The primary endpoints were post-HTx length of hospital stay (LOS) and one-year survival. Confounding was addressed by propensity score weighting using inverse probability of treatment. Propensity scores were calculated based on age, blood type, primary cardiac diagnosis, decade, VAD type, and allosensitization status. RESULTS A total of 1064 children underwent VAD prior to HTx between 2000 to 2018. Most underwent HTx ≥ 30 days post-VAD (70%). Infants made up 22% of both groups. Patients ≥ 12 years old were 42% of the < 30 days group and children 1 to 11 years comprised 47% of the ≥ 30 days group (p < 0.001). There was no difference in the prevalence of congenital heart disease vs. cardiomyopathy (p = 0.8) or high allosensitization status (p = 0.9) between groups. Post-HTx LOS was similar between groups (p = 0.11). One-year survival was lower in the < 30 days group (adjusted mortality HR 1.76, 95% CI 1.11-2.78, p = 0.016). CONCLUSIONS A longer duration of VAD support prior to HTx is associated with a one-year survival benefit in children, although questions of patient complexity, post-VAD complications and the impact on causality remain. Additional studies using linked databases to understand these factors will be needed to fully assess the optimal timing for post-VAD HTx.
Collapse
Affiliation(s)
- Arene Butto
- Pediatric Cardiology, Children's Healthcare of Atlanta, Atlanta, Georgia.
| | - Chad Y Mao
- Pediatric Cardiology, Children's Healthcare of Atlanta, Atlanta, Georgia
| | - Lydia Wright
- Pediatric Cardiology, Children's Healthcare of Atlanta, Atlanta, Georgia
| | - Martha Wetzel
- Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia
| | - Michael S Kelleman
- Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia
| | | | - Anne I Dipchand
- Labatt Family Heart Center, Hospital for Sick Children, Toronto, Ontario, Canada
| | - Kenneth R Knecht
- Arkansas Children's Hospital, University of Arkansas for Medical Sciences, Little Rock, Arkansas
| | - Zdenka Reinhardt
- Freeman Hospital, Thew Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle upon Tyne, England
| | | | - Chet Villa
- Cincinnati Children's Hospital, Cincinnati, Ohio
| | - William T Mahle
- Pediatric Cardiology, Children's Healthcare of Atlanta, Atlanta, Georgia
| |
Collapse
|
3
|
Joong A, Gossett JG, Blume ED, Thrush P, Pahl E, Mongé MC, Backer CL, Patel A. Variability in clinical decision-making for ventricular assist device implantation in pediatrics. Pediatr Transplant 2020; 24:e13840. [PMID: 33070459 DOI: 10.1111/petr.13840] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/03/2020] [Revised: 08/03/2020] [Accepted: 08/12/2020] [Indexed: 12/23/2022]
Abstract
BACKGROUND Minimal data exist on clinical decision-making in VAD implantation in pediatrics. This study aims to identify areas of consensus/variability among pediatric VAD physicians in determining eligibility and factors that guide decision-making. METHODS An 88-item survey with clinical vignettes was sent to 132 pediatric HT cardiologists and surgeons at 37 centers. Summary statistics are presented for the variables assessed. RESULTS Total respondents were 65 (72% cardiologists, 28% surgeons) whose centers implanted 1-5 (34%), 6-10 (40%), or >10 (26%) VADs in the past year. Consensus varied by patients' age, diagnosis, and Pedimacs profile. Highest agreement to offer VAD (97%) was a mechanically ventilated teenager with dilated cardiomyopathy. Patients stable on inotropes were less likely offered VAD (11%-25%). SV infant with Pedimacs profile 2 had the most varied responses: 37% offered VAD; estimated survival ranged from 15% to 90%. Variables considered for VAD eligibility included mild developmental delays (100% offered VAD), moderate-severe behavioral concerns (46%), cancer in remission >2 years (100%), active malignancy with good prognosis (68%) or uncertain prognosis (36%), and BMI >35 (74%) or <15 (69%). Most respondents (91%) would consider destination therapy VADs in pediatrics, though not currently feasible at 1/3 of centers. Factors with greatest influence on decision-making included HT candidacy, families' goals of care, and risks of complications. CONCLUSIONS Significant variation exists among pediatric VAD physicians when determining VAD eligibility and estimating survival, which can lead to differences in access to emerging technologies across institutions. Further work is needed to understand and mitigate these differences.
Collapse
Affiliation(s)
- Anna Joong
- Division of Pediatric Cardiology, Northwestern Feinberg School of Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA
| | - Jeffrey G Gossett
- Division of Pediatric Cardiology, Benioff Children's Hospital, University of San Francisco California, San Francisco, CA, USA
| | - Elizabeth D Blume
- Department of Cardiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Philip Thrush
- Division of Pediatric Cardiology, Northwestern Feinberg School of Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA
| | - Elfriede Pahl
- Division of Pediatric Cardiology, Northwestern Feinberg School of Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA
| | - Michael C Mongé
- Division of Pediatric Cardiovascular Surgery, Northwestern Feinberg School of Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA
| | - Carl L Backer
- Section of Pediatric Cardiothoracic Surgery, UK Healthcare Kentucky Children's Hospital, Lexington, KY, USA
| | - Angira Patel
- Division of Pediatric Cardiology, Northwestern Feinberg School of Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA
| |
Collapse
|
4
|
Bridge to Transplant with Ventricular Assist Device Support in Pediatric Patients with Single Ventricle Heart Disease. ASAIO J 2020; 66:205-211. [PMID: 30864969 DOI: 10.1097/mat.0000000000000983] [Citation(s) in RCA: 36] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Ventricular assist device (VAD) support for children with single ventricle (SV) heart disease remains challenging. We performed a single-center retrospective review of SV patients on VAD support and examined survival to transplant using the Kaplan-Meier method. Patients transplanted were compared with those who died on support. Between 2009 and 2017, there were 14 SV patients with 1,112 patient-days of VAD support. Stages of palliation included pre-Glenn (n = 5), Glenn (n = 5), and Fontan (n = 4). Eight patients (57%) were successfully bridged to transplant at a median 107 days. Deaths occurred early (n = 6, median 16 days) and in smaller patients (10.1 vs. 28.3 kg, P = 0.04). All Fontan patients survived to transplant, whereas only 20% of Glenn patients survived to transplant. Adverse events occurred in 79% (n = 11). Five patients met hospital discharge criteria, with two patients (one pre-Glenn, one Glenn) discharged and transplanted after 219 and 174 days of VAD support. All transplanted patients were discharged at a median 21 days posttransplant. SV patients in various stages of palliation can be successfully bridged to transplant with VAD support. With use of intracorporeal continuous-flow devices, longer-term support and hospital discharge are possible.
Collapse
|
5
|
|
6
|
|
7
|
Antithrombin Population Pharmacokinetics in Pediatric Ventricular Assist Device Patients. Pediatr Crit Care Med 2019; 20:1157-1163. [PMID: 31232851 DOI: 10.1097/pcc.0000000000002039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVES Describe the pharmacokinetics of antithrombin in pediatric patients undergoing ventricular assist device therapy and provide dosing recommendations for antithrombin in this population. DESIGN A retrospective population pharmacokinetic study was designed. SETTING Large tertiary care children's hospital Subject inclusion criteria consisted of less than 19 years old. PATIENTS Subjects less than 19 years old undergoing therapy with a HeartWare ventricular assist device (HeartWare, Framingham, MA) or Berlin EXCOR ventricular assist device (Berlin GmbH, Berlin, Germany), who received a dose of antithrombin with a postdose antithrombin activity level from January 1, 2011, to June 30, 2017. INTERVENTIONS Population pharmacokinetic analysis and simulation using NONMEM v.7.4 (Icon, PLC, Dublin, Ireland). MEASUREMENTS AND MAIN RESULTS A total of 41 patients met study criteria (median age, 5.8 years [interquartile range, 1.6-9.9 yr]), and 53.7% underwent therapy with the pulsatile Berlin EXCOR pediatric ventricular assist device (Berlin Heart GmbH, Berlin, Germany). All patients received unfractionated heparin continuous infusion at a mean ± SD dose of 29 ± 14 U/kg/hr. A total of 181 antithrombin doses (44.1 ± 24.6 U/kg/dose) were included, and baseline antithrombin activity levels were 77 ± 12 U/dL. Antithrombin activity levels were drawn a median 19.9 hours (interquartile range, 8.8-41.6 hr) after antithrombin dose. A one-compartment proportional error model best fit the data, with allometric scaling of fat-free mass providing a better model fit than actual body weight. Unfractionated heparin and baseline antithrombin were identified as significant covariates. A 50 U/kg dose of antithrombin had a simulated half-life 13.2 ± 6.6 hours. CONCLUSIONS Antithrombin should be dosed on fat-free mass in pediatric ventricular assist device patients. Unfractionated heparin dose and baseline antithrombin activity level should be considered when dosing antithrombin in pediatric ventricular assist device patients.
Collapse
|
8
|
Pediatric ventricular assist device support as a permanent therapy: Clinical reality. J Thorac Cardiovasc Surg 2019; 158:1438-1441. [DOI: 10.1016/j.jtcvs.2019.02.145] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/05/2019] [Revised: 02/15/2019] [Accepted: 02/22/2019] [Indexed: 02/01/2023]
|
9
|
Thangappan K, Morales DLS. Commentary: Are we there yet? Long-term ventricular assist device therapy in pediatric heart centers. J Thorac Cardiovasc Surg 2019; 158:1442-1443. [PMID: 31623810 DOI: 10.1016/j.jtcvs.2019.08.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/02/2019] [Revised: 08/02/2019] [Accepted: 08/02/2019] [Indexed: 11/30/2022]
Affiliation(s)
- Karthik Thangappan
- Department of Cardiovascular Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| | - David L S Morales
- Department of Cardiovascular Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
| |
Collapse
|
10
|
Navaratnam M, Maeda K, Hollander SA. Pediatric ventricular assist devices: Bridge to a new era of perioperative care. Paediatr Anaesth 2019; 29:506-518. [PMID: 30758099 DOI: 10.1111/pan.13609] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/15/2018] [Revised: 02/04/2019] [Accepted: 02/06/2019] [Indexed: 01/17/2023]
Abstract
Pediatric ventricular assist devices (VADs) are evolving as a standard therapy for end stage heart failure in children. Major recent developments include the increased use of continuous flow (CF) devices in children and increased experience with congenital heart disease (CHD) and outpatient management. In the current and future era anesthesiologists will encounter more children presenting for VAD implantation, subsequent procedures and heart transplantation. Successful perioperative management requires an understanding of the interaction between the patient's physiology and the device and a framework to troubleshoot problems. This review focuses on CF devices, VAD support for CHD and perioperative management of pulsatile and CF devices in the pediatric population.
Collapse
Affiliation(s)
- Manchula Navaratnam
- Pediatric Anesthesia, Stanford Children's Hospital, Stanford University Medical Center, Palo Alto, California
| | - Katsuhide Maeda
- Pediatric Cardiac Surgery, Stanford Children's Hospital, Stanford University Medical Center, Palo Alto, California
| | - Seth A Hollander
- Pediatric Cardiology, Stanford Children's Hospital, Stanford University Medical Center, Palo Alto, California
| |
Collapse
|
11
|
Adachi I, Spinner JA, Tunuguntla HP, Elias BA, Heinle JS. The miniaturized pediatric continuous-flow device: A successful bridge to heart transplant. J Heart Lung Transplant 2019; 38:789-793. [PMID: 31109819 DOI: 10.1016/j.healun.2019.04.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2019] [Revised: 04/18/2019] [Accepted: 04/24/2019] [Indexed: 10/26/2022] Open
Affiliation(s)
- Iki Adachi
- Congenital Heart Surgery, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas.
| | - Joseph A Spinner
- Pediatric Cardiology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas
| | - Hari P Tunuguntla
- Pediatric Cardiology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas
| | - Barbara A Elias
- Congenital Heart Surgery, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas
| | - Jeffrey S Heinle
- Congenital Heart Surgery, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas
| |
Collapse
|
12
|
Adachi I, Zea-Vera R, Tunuguntla H, Denfield SW, Elias B, John R, Teruya J, Fraser CD. Centrifugal-flow ventricular assist device support in children: A single-center experience. J Thorac Cardiovasc Surg 2019; 157:1609-1617.e2. [DOI: 10.1016/j.jtcvs.2018.12.045] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/18/2018] [Revised: 11/28/2018] [Accepted: 12/13/2018] [Indexed: 01/20/2023]
|
13
|
Fraser CD, Chacon-Portillo MA, Zea-Vera R, John R, Elias BA, Heinle JS, Mery CM, Tunuguntla HP, Cabrera AG, Price JF, Denfield SW, Dreyer WJ, Qureshi AM, Adachi I. Ventricular Assist Device Support: Single Pediatric Institution Experience Over Two Decades. Ann Thorac Surg 2019; 107:829-836. [DOI: 10.1016/j.athoracsur.2018.08.018] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/01/2018] [Revised: 07/30/2018] [Accepted: 08/13/2018] [Indexed: 11/28/2022]
|
14
|
Loforte A. The revolutionary nature of pediatric continuous-flow miniaturized devices. J Heart Lung Transplant 2019; 38:394-395. [PMID: 30691772 DOI: 10.1016/j.healun.2018.11.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2018] [Accepted: 11/14/2018] [Indexed: 10/27/2022] Open
Affiliation(s)
- Antonio Loforte
- Department of Cardiothoracic, Transplantation and Vascular Surgery, S. Orsola Hospital, Bologna University, Bologna, Italy.
| |
Collapse
|
15
|
Chan CHH, Diab S, Moody K, Frazier OH, Sampaio LC, Fraser CD, Teruya J, Adachi I. In Vitro Hemocompatibility Evaluation of Ventricular Assist Devices in Pediatric Flow Conditions: A Benchmark Study. Artif Organs 2018; 42:1028-1034. [DOI: 10.1111/aor.13165] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2017] [Revised: 03/29/2018] [Accepted: 03/29/2018] [Indexed: 12/21/2022]
Affiliation(s)
- Chris Hoi Houng Chan
- Cardiovascular Surgery Research Laboratories; Texas Heart Institute; Houston TX USA
| | - Sara Diab
- Cardiovascular Surgery Research Laboratories; Texas Heart Institute; Houston TX USA
- School of Medicine; University of Queensland; Brisbane QLD AUS
| | - Kayla Moody
- Cardiovascular Surgery Research Laboratories; Texas Heart Institute; Houston TX USA
| | - O Howard Frazier
- Cardiovascular Surgery Research Laboratories; Texas Heart Institute; Houston TX USA
| | - Luiz C. Sampaio
- Cardiovascular Surgery Research Laboratories; Texas Heart Institute; Houston TX USA
| | - Charles D. Fraser
- Division of Congenital Heart Surgery; Texas Children's Hospital; Houston TX USA
- Surgery and Pediatrics; Houston TX USA
| | - Jun Teruya
- Pathology & Immunology; Baylor College of Medicine; Houston TX USA
- Transfusion Medicine and Coagulation; Texas Children's Hospital; Houston TX USA
| | - Iki Adachi
- Division of Congenital Heart Surgery; Texas Children's Hospital; Houston TX USA
- Surgery and Pediatrics; Houston TX USA
| |
Collapse
|
16
|
Mechanical circulatory support challenges in pediatric and (adult) congenital heart disease. Curr Opin Organ Transplant 2018; 23:301-307. [DOI: 10.1097/mot.0000000000000522] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
17
|
Sinha L, Yerebakan C. The first integrated aortic turbine venous-assist system is born. J Thorac Cardiovasc Surg 2018; 156:304-305. [PMID: 29753509 DOI: 10.1016/j.jtcvs.2018.04.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/01/2018] [Accepted: 04/06/2018] [Indexed: 11/19/2022]
Affiliation(s)
- Lok Sinha
- Division of Cardiovascular Surgery, Children's National Heart Institute, Children's National Health System, The George Washington University School of Medicine and Health Sciences, Washington, DC
| | - Can Yerebakan
- Division of Cardiovascular Surgery, Children's National Heart Institute, Children's National Health System, The George Washington University School of Medicine and Health Sciences, Washington, DC.
| |
Collapse
|
18
|
Abstract
Similar to the adult experience, the use of continuous-flow ventricular assist devices (VADs) has been increasing in the pediatric population. According to the PediMACS registry, continuous-flow VAD currently accounts for >60% of the durable device implantations in the U.S. Nonetheless, the continuous-flow VADs currently in use are designed for adults; this inevitably causes the patient-device size mismatch issue, especially when applied for small children. Pulsatile VADs, therefore, represent the only practical option for this group of patients despite the known risk profile of pulsatile VADs. To address such a frustrating reality, the National Heart, Lung, and Blood Institute (NHLBI) launched the Pediatric Circulatory Support Program in 2004, which is the predecessor of the so-called PumpKIN (Pump for Kids, Infants, and Neonates) program. The goal of this program was to develop mechanical circulatory support devices specifically designed for small children. As a result of extensive efforts of the multi-disciplinary team involving clinicians, scientists, manufactures, and federal agencies, the Infant Jarvik 2015, one of the original devices within the Pediatric Circulatory Support Program, has become the first continuous-flow VAD specifically designed for small children that obtained the Investigational Device Exemption (IDEs) from the U.S. Food and Drug Administration (FDA). This approval is a prerequisite to initiate a clinical trial (i.e., the PumpKIN trial). This article describes the history, current status, and future perspectives of this extremely challenging project, with a focus on the lessons we have learned over the decade.
Collapse
Affiliation(s)
- Iki Adachi
- Director, Mechanical Circulatory Support Program, Congenital Heart Surgery, Texas Children's Hospital, Houston, TX, USA.,Associate Surgeon, Congenital Heart Surgery, Texas Children's Hospital, Houston, TX, USA.,Associate Professor, Department of Surgery and Pediatrics, Baylor College of Medicine, Houston, TX, USA
| |
Collapse
|
19
|
Nasr VG, Twite MD, Walker SG, Kussman BD, Motta P, Mittnacht AJC, Mossad EB. Selected 2017 Highlights in Congenital Cardiac Anesthesia. J Cardiothorac Vasc Anesth 2018; 32:1546-1555. [PMID: 29699846 DOI: 10.1053/j.jvca.2018.03.027] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/16/2018] [Indexed: 02/06/2023]
Affiliation(s)
- Vivian G Nasr
- Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, MA
| | - Mark D Twite
- Department of Anesthesiology, University of Colorado and Children's Hospital Colorado, Anschutz Medical Campus, Aurora, CO
| | - Scott G Walker
- Department of Anesthesiology, Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN
| | - Barry D Kussman
- Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, MA
| | - Pablo Motta
- Division of Pediatric Cardiovascular Anesthesia, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
| | - Alexander J C Mittnacht
- Department of Anesthesiology, Perioperative and Pain Medicine, the Icahn School of Medicine at Mount Sinai, New York, NY.
| | - Emad B Mossad
- Division of Pediatric Cardiovascular Anesthesia, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
| |
Collapse
|
20
|
Villa CR, Lorts A, Morales DL. Pediatric continuous-flow left ventricular assist devices: No longer just a bridge? The changing of a mindset! J Thorac Cardiovasc Surg 2017; 154:1362-1363. [DOI: 10.1016/j.jtcvs.2017.05.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/04/2017] [Accepted: 05/08/2017] [Indexed: 10/19/2022]
|
21
|
Davies RR. Heading toward the future of pediatric heart failure with continuous-flow ventricular assist devices. J Thorac Cardiovasc Surg 2017; 154:1356-1357. [DOI: 10.1016/j.jtcvs.2017.05.097] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/26/2017] [Accepted: 05/31/2017] [Indexed: 11/24/2022]
|